American College of Gastroenterology
P.O. Box 342260
Bethesda, MD 20827-2260
American Gastroenterological Association
4930 Del Ray Avenue
Bethesda, MD 20814
Crohn's and Colitis Foundation of America,Inc.
386 Park Avenue South, 17th Floor
New York, NY 10016-8804
National Digestive Diseases Information Clearinghouse
2 Information Way
Bethesda, MD 20892-3570
Foundation for Clinical Research in IBD
Information on this website is not intended to replace the advice of your physician(s). Please consider what you learn here a starting point for a conversation with your physician. All care of ulcerative proctitis and related conditions must be guided by the appropriate healthcare professional. CANASA® is a prescription drug.
CANASA® is available by prescription only.
CANASA® 1000 mg Suppositories are indicated for the treatment of active ulcerative proctitis.
CANASA® is contraindicated in patients who have demonstrated hypersensitivity to mesalamine (5-aminosalicylic acid) or to the suppository vehicle [saturated fatty acid esters (Hard Fat, NF)], or to salicylates (including Aspirin).
As with other mesalamine containing products, less common but possibly serious side effects such as acute intolerance syndrome, pericarditis and pancolitis may occur.
Patients on CANASA® 1000 mg, especially those on concurrent oral products which contain or release mesalamine and those with pre-existing renal disease, should be carefully monitored with urinalysis, BUN and creatinine testing.
Caution should be exercised when CANASA® suppositories are initially used in patients known to be allergic to sulfasalazine.
CANASA® was generally well tolerated in clinical studies. The most common side effects of CANASA® are dizziness (3%), rectal pain (1.8%), fever (1.2%), rash (1.2%), acne (1.2%), and colitis (1.2%).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.FDA.gov/medwatch, or call 1-800-FDA-1088.